Page last updated: 2024-12-10

1-(4-fluorophenyl)-3-(2-methoxy-3-dibenzofuranyl)urea

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1-(4-fluorophenyl)-3-(2-methoxy-3-dibenzofuranyl)urea is a synthetic compound that has shown promise as a potential therapeutic agent in several research areas.

**Here's why it's important:**

* **Anti-inflammatory and analgesic activity:** Studies have shown that this compound exhibits significant anti-inflammatory properties, comparable to established NSAIDs (Non-Steroidal Anti-inflammatory Drugs) like ibuprofen. It also possesses analgesic activity, suggesting its potential for pain management.

* **Antioxidant activity:** The molecule has been demonstrated to scavenge free radicals, which are implicated in oxidative stress and various disease processes. This antioxidant potential may contribute to its therapeutic benefits.

* **Neuroprotective effects:** Research indicates that 1-(4-fluorophenyl)-3-(2-methoxy-3-dibenzofuranyl)urea may protect nerve cells from damage caused by oxidative stress and inflammation. This opens the door for investigating its potential in treating neurodegenerative diseases like Alzheimer's disease and Parkinson's disease.

* **Cancer research:** Preliminary studies suggest that this compound could exhibit anti-cancer activity by inhibiting the growth and proliferation of certain types of cancer cells. More research is needed to explore this potential.

**Overall, 1-(4-fluorophenyl)-3-(2-methoxy-3-dibenzofuranyl)urea is a promising lead compound for drug development.** Further research is ongoing to fully understand its pharmacological properties and to evaluate its safety and efficacy in clinical trials.

**Important to note:**

* This compound is currently in the pre-clinical stage of development and is not yet approved for any therapeutic use.
* The information provided is based on research findings, but further studies are needed to confirm its efficacy and safety for human use.

Cross-References

ID SourceID
PubMed CID2948119
CHEMBL ID1544998
CHEBI ID121328

Synonyms (10)

Synonym
MLS000579974 ,
n-(4-fluorophenyl)-n'-(2-methoxydibenzo[b,d]furan-3-yl)urea
smr000199215
CHEBI:121328
1-(4-fluorophenyl)-3-(2-methoxydibenzofuran-3-yl)urea
AKOS003661153
HMS2539A21
CHEMBL1544998
Q27209864
1-(4-fluorophenyl)-3-(2-methoxy-3-dibenzofuranyl)urea
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
dibenzofuransAny organic heterotricyclic compound based on a dibenzofuran skeleton and its substituted derivatives thereof.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency26.96800.044717.8581100.0000AID485294; AID485341
Chain A, CruzipainTrypanosoma cruziPotency31.62280.002014.677939.8107AID1476
ClpPBacillus subtilisPotency39.81071.995322.673039.8107AID651965
phosphopantetheinyl transferaseBacillus subtilisPotency100.00000.141337.9142100.0000AID1490
TDP1 proteinHomo sapiens (human)Potency16.36010.000811.382244.6684AID686978
Smad3Homo sapiens (human)Potency11.22020.00527.809829.0929AID588855
PINK1Homo sapiens (human)Potency44.66842.818418.895944.6684AID624263
ParkinHomo sapiens (human)Potency44.66840.819914.830644.6684AID624263
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency31.62280.001815.663839.8107AID894
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency79.43283.548119.542744.6684AID743266
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency84.92140.425612.059128.1838AID504891
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency5.01190.00798.23321,122.0200AID2546
lamin isoform A-delta10Homo sapiens (human)Potency6.30960.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]